Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nanoviricides Inc
(NY:
NNVC
)
1.900
+0.060 (+3.26%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nanoviricides Inc
< Previous
1
2
3
Next >
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
August 19, 2024
Via
ACCESSWIRE
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
August 08, 2024
Via
ACCESSWIRE
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
August 06, 2024
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?
August 02, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 2, 2024) - Investorideas.com, a go-to investing platform covering biotech and...
Via
Newsfile
Exposures
COVID-19
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
June 11, 2024
Via
ACCESSWIRE
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
June 04, 2024
Via
ACCESSWIRE
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
August 01, 2024
Via
ACCESSWIRE
COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
July 24, 2024
Via
ACCESSWIRE
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
July 11, 2024
Via
ACCESSWIRE
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
July 01, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
June 24, 2024
Via
ACCESSWIRE
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
May 29, 2024
Via
ACCESSWIRE
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
May 20, 2024
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
May 15, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model
June 20, 2024
Via
ACCESSWIRE
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
May 29, 2024
Via
AB Newswire
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
May 23, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against RSV
May 14, 2024
Via
ACCESSWIRE
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
May 10, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
May 08, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
May 06, 2024
Via
ACCESSWIRE
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
April 30, 2024
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
February 15, 2024
Via
ACCESSWIRE
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
February 01, 2024
Via
ACCESSWIRE
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
January 29, 2024
Via
ACCESSWIRE
NanoViricides to Present at the Biotech Showcase in San Fransisco
January 04, 2024
Via
ACCESSWIRE
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
November 28, 2023
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
November 15, 2023
Via
ACCESSWIRE
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
November 14, 2023
Via
ACCESSWIRE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
October 16, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.